| Followers | 60 |
| Posts | 11377 |
| Boards Moderated | 0 |
| Alias Born | 01/31/2008 |
Friday, June 27, 2025 3:36:00 AM
Most of that distrust is due to bureaucratic misconduct and is well-deserved:
The Tuskegee Syphilis Study was a infamous clinical study conducted in Macon County, Alabama, from 1932 to 1972, by the U.S. Public Health Service. It involved 600 African American men, 399 with syphilis and a control group of 201, who were deceived into participating under the false promise of free medical care. The study aimed to observe the natural progression of untreated syphilis in Black men, even after penicillin became an effective treatment. Researchers deliberately withheld information about the men's diagnosis and treatment options, including the availability of penicillin, leading to severe health consequences for the participants and their families. The study was eventually halted after public outcry and media exposure.
Any private company trying to pull that crap would be sued into oblivion. But of course the govt is often immune from lawsuit, and even grants that to companies to push products of unproven safety long-term safety, like untested RNA covid vaccines.
That said, I seriously doubt patient recruitment explains the difference in costs, as there is virtually no cost to asking a patient if he wants to be part of a clinical trial, which is the initial decision node. They arent paying people to say yes.
The cost starts if the patient agrees to the trial, in terms of processing, data collection, monitoring and doctor visits.
The Tuskegee Syphilis Study was a infamous clinical study conducted in Macon County, Alabama, from 1932 to 1972, by the U.S. Public Health Service. It involved 600 African American men, 399 with syphilis and a control group of 201, who were deceived into participating under the false promise of free medical care. The study aimed to observe the natural progression of untreated syphilis in Black men, even after penicillin became an effective treatment. Researchers deliberately withheld information about the men's diagnosis and treatment options, including the availability of penicillin, leading to severe health consequences for the participants and their families. The study was eventually halted after public outcry and media exposure.
Any private company trying to pull that crap would be sued into oblivion. But of course the govt is often immune from lawsuit, and even grants that to companies to push products of unproven safety long-term safety, like untested RNA covid vaccines.
That said, I seriously doubt patient recruitment explains the difference in costs, as there is virtually no cost to asking a patient if he wants to be part of a clinical trial, which is the initial decision node. They arent paying people to say yes.
The cost starts if the patient agrees to the trial, in terms of processing, data collection, monitoring and doctor visits.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM

